Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.12
BICX's Cash to Debt is ranked lower than
99.99% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 0.42 vs. BICX: 1.12 )
Ranked among companies with meaningful Cash to Debt only.
BICX' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.14 Max: No Debt
Current: 1.12
Equity to Asset -2.85
BICX's Equity to Asset is ranked lower than
99.99% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 0.49 vs. BICX: -2.85 )
Ranked among companies with meaningful Equity to Asset only.
BICX' s Equity to Asset Range Over the Past 10 Years
Min: -14.42  Med: 0.12 Max: 0.99
Current: -2.85
-14.42
0.99
F-Score: 4
Z-Score: -16.67
M-Score: -9.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -320.03
BICX's Operating margin (%) is ranked lower than
99.99% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 6.99 vs. BICX: -320.03 )
Ranked among companies with meaningful Operating margin (%) only.
BICX' s Operating margin (%) Range Over the Past 10 Years
Min: -553.3  Med: -183.83 Max: -44.56
Current: -320.03
-553.3
-44.56
Net-margin (%) -376.85
BICX's Net-margin (%) is ranked lower than
99.99% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 4.82 vs. BICX: -376.85 )
Ranked among companies with meaningful Net-margin (%) only.
BICX' s Net-margin (%) Range Over the Past 10 Years
Min: -536.92  Med: -187.38 Max: -52.98
Current: -376.85
-536.92
-52.98
ROA (%) -178.10
BICX's ROA (%) is ranked lower than
99.99% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 4.28 vs. BICX: -178.10 )
Ranked among companies with meaningful ROA (%) only.
BICX' s ROA (%) Range Over the Past 10 Years
Min: -1550  Med: -123.71 Max: -18.07
Current: -178.1
-1550
-18.07
ROC (Joel Greenblatt) (%) -31545.45
BICX's ROC (Joel Greenblatt) (%) is ranked lower than
99.99% of the 239 Companies
in the Global Medical Care industry.

( Industry Median: 19.38 vs. BICX: -31545.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BICX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -102360  Med: -23057.15 Max: -6254.55
Current: -31545.45
-102360
-6254.55
Revenue Growth (3Y)(%) -9.10
BICX's Revenue Growth (3Y)(%) is ranked lower than
99.99% of the 175 Companies
in the Global Medical Care industry.

( Industry Median: 7.80 vs. BICX: -9.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BICX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -18.9 Max: 14.5
Current: -9.1
0
14.5
EBITDA Growth (3Y)(%) 74.70
BICX's EBITDA Growth (3Y)(%) is ranked lower than
99.99% of the 141 Companies
in the Global Medical Care industry.

( Industry Median: 7.90 vs. BICX: 74.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BICX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 44.2 Max: 74.7
Current: 74.7
0
74.7
EPS Growth (3Y)(%) 44.20
BICX's EPS Growth (3Y)(%) is ranked lower than
99.99% of the 124 Companies
in the Global Medical Care industry.

( Industry Median: 6.80 vs. BICX: 44.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BICX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 44.2
Current: 44.2
0
44.2
» BICX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with BICX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care
Compare:OTCPK:PFHO, OTCPK:SPIN, AMEX:SSY, AMEX:HH, OTCPK:WNDM, AMEX:AMS, OTCPK:GNOW, OTCPK:USNU, OTCPK:GRST, OTCPK:CPAI, OTCPK:DYII, OTCPK:BNKL, NAS:JYNT, OTCPK:AMEH, OTCPK:CCEL, OTCPK:FCHS, OTCPK:FDNH, OTCPK:CVHIF, OTCPK:CRNJF, OTCPK:BRRZF » details
BioCorRx Inc is an alcohol treatment and rehabilitation company. It provides an alcoholism treatment program that empowers patients to succeed in their overall recovery.

Fresh Start Private Management, Inc., a Nevada corporation on January 28, 2008 as Cetrone Energy Company. On July 26, 2010, the Company changed its name to Fresh Start Private Management Inc. Through its wholly owned subsidiary, it is an alcohol rehabilitation and treatment center. The company was established in January 2010 and is currently operating in Santa Ana, California. Its alcohol rehabilitation program consists of a Naltrexone implant that is placed under the skin in the lower abdomen coupled with life counseling sessions from specialized counselors. The Company operates within the Specialty Hospitals, Expert Psychiatric industry, specifically within the industry subsets of Alcoholism Rehabilitation Hospital. It has created an innovative alcohol treatment program that empowers patients to succeed in their overall recovery. The Company offers a treatment philosophy that combines medical intervention, a singular focus and a comprehensive approach, and a focus on family and friends. It has been operating for approximately 36 months and has treated over 150 patients. Currently, it is treating about 2 to 3 patients per week. The alcohol treatment services costs an average of $49,300 per patient and is typically covered by insurance. The Company faces competition with the other rehabilitation service providers.

Ratios

vs
industry
vs
history
P/S 13.33
BICX's P/S is ranked lower than
99.99% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. BICX: 13.33 )
Ranked among companies with meaningful P/S only.
BICX' s P/S Range Over the Past 10 Years
Min: 0.95  Med: 5 Max: 185
Current: 13.33
0.95
185
EV-to-EBIT -3.13
BICX's EV-to-EBIT is ranked lower than
99.99% of the 181 Companies
in the Global Medical Care industry.

( Industry Median: 20.01 vs. BICX: -3.13 )
Ranked among companies with meaningful EV-to-EBIT only.
BICX' s EV-to-EBIT Range Over the Past 10 Years
Min: -180  Med: -6 Max: -0.7
Current: -3.13
-180
-0.7
EV-to-EBITDA -3.21
BICX's EV-to-EBITDA is ranked lower than
99.99% of the 195 Companies
in the Global Medical Care industry.

( Industry Median: 14.08 vs. BICX: -3.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
BICX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -180  Med: -6.4 Max: -0.7
Current: -3.21
-180
-0.7
Current Ratio 0.55
BICX's Current Ratio is ranked lower than
99.99% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 1.39 vs. BICX: 0.55 )
Ranked among companies with meaningful Current Ratio only.
BICX' s Current Ratio Range Over the Past 10 Years
Min: 0.05  Med: 0.52 Max: 5.44
Current: 0.55
0.05
5.44
Quick Ratio 0.55
BICX's Quick Ratio is ranked lower than
99.99% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 1.28 vs. BICX: 0.55 )
Ranked among companies with meaningful Quick Ratio only.
BICX' s Quick Ratio Range Over the Past 10 Years
Min: 0.05  Med: 0.52 Max: 5.44
Current: 0.55
0.05
5.44
Days Sales Outstanding 20.98
BICX's Days Sales Outstanding is ranked lower than
99.99% of the 201 Companies
in the Global Medical Care industry.

( Industry Median: 43.21 vs. BICX: 20.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
BICX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.05  Med: 160.29 Max: 452.04
Current: 20.98
11.05
452.04
Days Payable 2.00
BICX's Days Payable is ranked lower than
99.99% of the 154 Companies
in the Global Medical Care industry.

( Industry Median: 38.51 vs. BICX: 2.00 )
Ranked among companies with meaningful Days Payable only.
BICX' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2
Current: 2
0
2

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.70
BICX's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 124 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. BICX: -17.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BICX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -19  Med: -7.3 Max: 39.3
Current: -17.7
-19
39.3

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 3.00
BICX's Price/Median PS Value is ranked lower than
99.99% of the 198 Companies
in the Global Medical Care industry.

( Industry Median: 1.07 vs. BICX: 3.00 )
Ranked among companies with meaningful Price/Median PS Value only.
BICX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.25  Med: 1 Max: 13
Current: 3
0.25
13
Earnings Yield (Greenblatt) (%) -32.01
BICX's Earnings Yield (Greenblatt) (%) is ranked lower than
99.99% of the 224 Companies
in the Global Medical Care industry.

( Industry Median: 4.10 vs. BICX: -32.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BICX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -58.35  Med: 0 Max: 0
Current: -32.01
-58.35
0

More Statistics

Revenue (TTM) (Mil) $0.61
EPS (TTM) $ -0.02
Beta0.92
Short Percentage of Float0.00%
52-Week Range $0.02 - 0.07
Shares Outstanding (Mil)166.09
» More Articles for BICX

Headlines

Articles On GuruFocus.com
Health Care Sector in an Upward Climb in June Jun 12 2014 
Two Promising Health Care Stocks with Market Capitalizations Under $500 Million Jun 11 2014 

More From Other Websites
BIOCORRX INC. Financials Aug 24 2016
BIOCORRX INC. Files SEC form 10-Q, Quarterly Report Aug 17 2016
BioCorRx, Inc. Announces Agreement With Dr. David Gastfriend to Provide Strategic Initiative and... Aug 17 2016
BioCorRx Announces License Agreement With TheraKine Ltd. to Develop New Injectable Naltrexone... Aug 03 2016
BIOCORRX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Aug 03 2016
BioCorRx Retains MZ Group as Investor Relations Advisor Jul 20 2016
BioCorRx Launches R&D Initiative to Pursue FDA Approval for Naltrexone Implant Jul 14 2016
BIOCORRX INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... Jul 06 2016
BIOCORRX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Jun 21 2016
Alpine Creek and BioCorRx Announce Major Investment Into BioCorRx Jun 20 2016
BIOCORRX INC. Files SEC form 10-Q, Quarterly Report May 23 2016
BIOCORRX INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... May 20 2016
BIOCORRX INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial... Apr 18 2016
BIOCORRX INC. Files SEC form 10-K, Annual Report Apr 14 2016
BioCorRx's Program to Help Beat Alcohol and Opioid Addiction Now in 20 Locations and Growing in Time... Apr 04 2016
BIOCORRX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Mar 18 2016
BIOCORRX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Feb 18 2016
BIOCORRX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Feb 16 2016
BIOCORRX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Feb 10 2016
BIOCORRX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Jan 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)